Cargando…

Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases

It was recently reported that frailty status can negatively influence the clinical course of patients with inflammatory bowel diseases (IBDs). Our recent study demonstrated that 20% of patients with an IBD are frail, and disease activity increases the risk of frailty. In the present study, we prospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvatori, Silvia, Marafini, Irene, Franchin, Martina, Lavigna, Diletta, Brigida, Mattia, Venuto, Chiara, Biancone, Livia, Calabrese, Emma, Giannarelli, Diana, Monteleone, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095533/
https://www.ncbi.nlm.nih.gov/pubmed/37048741
http://dx.doi.org/10.3390/jcm12072658
_version_ 1785024106640441344
author Salvatori, Silvia
Marafini, Irene
Franchin, Martina
Lavigna, Diletta
Brigida, Mattia
Venuto, Chiara
Biancone, Livia
Calabrese, Emma
Giannarelli, Diana
Monteleone, Giovanni
author_facet Salvatori, Silvia
Marafini, Irene
Franchin, Martina
Lavigna, Diletta
Brigida, Mattia
Venuto, Chiara
Biancone, Livia
Calabrese, Emma
Giannarelli, Diana
Monteleone, Giovanni
author_sort Salvatori, Silvia
collection PubMed
description It was recently reported that frailty status can negatively influence the clinical course of patients with inflammatory bowel diseases (IBDs). Our recent study demonstrated that 20% of patients with an IBD are frail, and disease activity increases the risk of frailty. In the present study, we prospectively monitored this subgroup of frail patients, assessed whether the frailty status was reversible, and analyzed factors associated with frailty reversibility. Of the sixty-four frail patients with IBD enrolled, five (8%) were lost during the follow-up period and one (2%) underwent a colectomy. Eleven out of the fifty-eight (19%) patients maintained a frail phenotype during a median follow-up of 8 months (range 6–19 months), and thirty-five (60%) and twelve (21%) became pre-frail or fit, respectively. A comparison of the 58 patients at baseline and at the end of the study showed that frail phenotype reversibility occurred more frequently in patients who achieved clinical remission. A multivariate analysis showed that the improvement of the frail phenotype was inversely correlated with the persistence of clinically active disease (OR:0.1; 95% CI: 0.02–0.8) and a history of extra-intestinal manifestations (OR:0.1; 95% CI: 0.01–0.6) and positively correlated with the use of biologics (OR: 21.7; 95% CI: 3.4–263). Data indicate that the frail phenotype is a reversible condition in most IBD patients, and such a change relies on the improvement in disease activity.
format Online
Article
Text
id pubmed-10095533
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100955332023-04-13 Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases Salvatori, Silvia Marafini, Irene Franchin, Martina Lavigna, Diletta Brigida, Mattia Venuto, Chiara Biancone, Livia Calabrese, Emma Giannarelli, Diana Monteleone, Giovanni J Clin Med Article It was recently reported that frailty status can negatively influence the clinical course of patients with inflammatory bowel diseases (IBDs). Our recent study demonstrated that 20% of patients with an IBD are frail, and disease activity increases the risk of frailty. In the present study, we prospectively monitored this subgroup of frail patients, assessed whether the frailty status was reversible, and analyzed factors associated with frailty reversibility. Of the sixty-four frail patients with IBD enrolled, five (8%) were lost during the follow-up period and one (2%) underwent a colectomy. Eleven out of the fifty-eight (19%) patients maintained a frail phenotype during a median follow-up of 8 months (range 6–19 months), and thirty-five (60%) and twelve (21%) became pre-frail or fit, respectively. A comparison of the 58 patients at baseline and at the end of the study showed that frail phenotype reversibility occurred more frequently in patients who achieved clinical remission. A multivariate analysis showed that the improvement of the frail phenotype was inversely correlated with the persistence of clinically active disease (OR:0.1; 95% CI: 0.02–0.8) and a history of extra-intestinal manifestations (OR:0.1; 95% CI: 0.01–0.6) and positively correlated with the use of biologics (OR: 21.7; 95% CI: 3.4–263). Data indicate that the frail phenotype is a reversible condition in most IBD patients, and such a change relies on the improvement in disease activity. MDPI 2023-04-03 /pmc/articles/PMC10095533/ /pubmed/37048741 http://dx.doi.org/10.3390/jcm12072658 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Salvatori, Silvia
Marafini, Irene
Franchin, Martina
Lavigna, Diletta
Brigida, Mattia
Venuto, Chiara
Biancone, Livia
Calabrese, Emma
Giannarelli, Diana
Monteleone, Giovanni
Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases
title Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases
title_full Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases
title_fullStr Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases
title_full_unstemmed Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases
title_short Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases
title_sort reversibility of frail phenotype in patients with inflammatory bowel diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095533/
https://www.ncbi.nlm.nih.gov/pubmed/37048741
http://dx.doi.org/10.3390/jcm12072658
work_keys_str_mv AT salvatorisilvia reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases
AT marafiniirene reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases
AT franchinmartina reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases
AT lavignadiletta reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases
AT brigidamattia reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases
AT venutochiara reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases
AT bianconelivia reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases
AT calabreseemma reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases
AT giannarellidiana reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases
AT monteleonegiovanni reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases